Education
About Us
Working with TipRanks
Follow Us
Prophase Labs (PRPH)
NASDAQ:PRPH
Top Page
Prophase Labs
(NASDAQ:PRPH)
34Underperform
Prophase Labs (PRPH) vs. S&P 500 (SPY)
Market Cap
$12.07M
Dividend YieldN/A
Average Volume (3M)7.77M
Price to Earnings (P/E)―
Beta (1Y)-1.16
Revenue Growth-79.66%
EPS Growth-141.87%
CountryUS
Employees113
SectorHealthcare
Sector Strength62
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.50
Shares Outstanding29,874,030
10 Day Avg. Volume2,690,533
30 Day Avg. Volume7,774,282
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.58
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Prophase Labs Business Overview & Revenue Model
Company DescriptionProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
How the Company Makes MoneyProphase Labs makes money through the sale of its consumer health products. The company's revenue is primarily generated from its flagship product line, which includes over-the-counter remedies such as Cold-EEZE, a zinc gluconate lozenge formulated to reduce the duration of the common cold. In addition to Cold-EEZE, Prophase Labs offers various dietary supplements and health products that contribute to its revenue streams. The company sells its products through multiple distribution channels, including retail stores, pharmacies, and online platforms, which help it reach a broad consumer base. Significant partnerships with retailers and distributors enhance its market presence and facilitate the availability of its products to a wide audience.
Prophase Labs Financial Statement Overview
Summary
Prophase Labs is facing financial challenges with declining revenues and profitability, increased leverage, and negative cash flows. The company needs to address operational inefficiencies and stabilize its financial performance to improve its financial health.Income Statement
Prophase Labs has experienced significant revenue volatility with a sharp decline from 2022 to TTM (Trailing-Twelve-Months). The gross profit margin is negative due to costs exceeding revenues, and net profit margin is also negative, indicating unprofitability. Although the company saw a revenue surge in 2022, recent periods show a reversal in this trend.40
Negative
Balance Sheet
The debt-to-equity ratio has increased over time, suggesting rising leverage. The company’s stockholders' equity has decreased, impacting financial stability. However, the equity ratio remains moderately healthy, indicating a fair proportion of assets financed by equity.45
Neutral
Cash Flow
Prophase Labs exhibits negative free cash flow growth, and operating cash flow is consistently negative, highlighting cash management challenges. The operating cash flow to net income ratio suggests inefficiencies in converting net income to cash.35
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 12.75M | 44.38M | 122.65M | 79.04M | 14.51M | 9.88M | Gross Profit |
| -4.13M | 16.24M | 70.65M | 32.81M | 4.61M | 2.62M | EBIT |
| -35.41M | -21.61M | 23.59M | 9.80M | -3.98M | -3.24M | EBITDA |
| -27.25M | -14.83M | 28.73M | 11.39M | -1.49M | -2.71M | Net Income Common Stockholders |
| -27.76M | -16.78M | 18.46M | 6.27M | -2.42M | -3.01M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 12.35M | 4.74M | 17.44M | 17.26M | 8.46M | 1.36M | Total Assets |
| 22.18M | 91.93M | 87.65M | 89.30M | 31.41M | 12.27M | Total Debt |
| 0.00 | 21.38M | 6.96M | 14.90M | 14.72M | 0.00 | Net Debt |
| -12.35M | 19.77M | -2.15M | 6.49M | 7.91M | -434.00K | Total Liabilities |
| 6.56M | 42.54M | 24.02M | 30.67M | 20.85M | 1.04M | Stockholders Equity |
| 15.62M | 49.38M | 63.63M | 58.63M | 10.56M | 11.23M |
| Cash Flow | Free Cash Flow | ||||
| -16.63M | -14.50M | 24.63M | -17.85M | -4.28M | -1.07M | Operating Cash Flow |
| -14.18M | -11.35M | 28.55M | -13.62M | -2.59M | -841.00K | Investing Cash Flow |
| 1.20M | -1.37M | -2.08M | -19.67M | -1.02M | 5.54M | Financing Cash Flow |
| 13.37M | 5.76M | -26.02M | 35.13M | 9.99M | -5.82M |
Prophase Labs Technical Analysis
Negative
0.39
Price Trends
0.40
Negative
0.56
Negative
1.69
Negative
Market Momentum
>-0.01
Negative
47.13
Neutral
43.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPH, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.40, and below the 200-day MA of 1.69, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 43.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRPH.
Prophase Labs Risk Analysis
Prophase Labs disclosed 63 risk factors in its most recent earnings report. Prophase Labs reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prophase Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $303.95M | ― | -25.76% | ― | -2.09% | -13.01% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
44 Neutral | $62.50M | ― | -120.52% | ― | 1.80% | 33.06% | |
43 Neutral | $7.16M | ― | -18.06% | ― | -30.19% | 75.92% | |
42 Neutral | $13.87B | ― | -94.89% | ― | ― | 80.00% | |
39 Underperform | $11.01M | ― | -53.65% | ― | -88.70% | -3.48% | |
34 Underperform | $12.07M | ― | -58.71% | ― | -79.66% | -141.87% |
* Healthcare Sector Average
Performance Comparison
PRPH
Prophase Labs
0.35
-6.23
-94.68%
CYRX
CryoPort
5.44
-13.12
-70.69%
CTSO
Cytosorbents
0.99
0.03
3.13%
SMMT
Summit Therapeutics
18.91
15.37
434.18%
AYTU
Aytu BioScience
1.07
-2.13
-66.56%
CODX
Co-Diagnostics
0.32
-0.83
-72.17%
Prophase Labs Earnings Call Summary
Earnings Call Date: Mar 31, 2025 | % Change Since: -11.36% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Neutral
The call presented a mix of optimism about future liquidity events and strategic restructuring achievements, balanced by concerns over current financial tightness and low stock price. The company is focusing on turning around its financial position through potential collections and asset sales.Highlights
Potential $50 Million Collection from COVID Testing
Crown Medical Collections believes they can collect $50 million from outstanding COVID testing accounts receivable, significantly boosting liquidity.
Sale of Formalize Manufacturing
Formalize Manufacturing was sold for $23 million, which was used to retire most of the company's debt, improving the balance sheet.
Nebula Genomics Restructuring
Nebula Genomics has been restructured with a focus on D to C business, potentially becoming a profit generator in the near future.
Cutting Overhead and Streamlining Operations
Significant reductions in overhead and headcount have been implemented, positioning the company for improved profitability in future quarters.
Exciting Prospects for B Smart Esophageal Cancer Test
The B Smart esophageal cancer test is poised for commercialization, with potential partnerships with large diagnostic companies being explored.
Lowlights
Cash Position and Capital Tightness
Current cash position is about $700K, leading to tight capital constraints and reliance on potential loans and asset sales.
Stock Price and Reverse Split Concerns
Stock price is trading under $1, raising concerns about a potential reverse split to maintain NASDAQ listing compliance.
Delayed Financial Recovery
Despite strategic moves, the company is still facing delays in becoming profitable due to previous high overheads and missteps.
Challenges in Commercializing New Products
Concerns were raised about the cost and feasibility of commercializing the B Smart test without significant dilution or financial risk.
Company Guidance
During the call, ProPhase Labs, Inc. CEO Ted Karkus provided guidance on several key metrics and future plans. He highlighted the company's current position and potential liquidity events, including a significant $73 million expected collection from COVID testing accounts receivable, with $50 million anticipated net proceeds. Karkus discussed plans to commercialize the B Smart esophageal cancer test without incurring high costs, emphasizing strategic partnerships as a preferred approach. He mentioned potential sales of subsidiaries like Nebula Genomics, which was acquired for approximately $14 million, as a means to bolster cash flow. The company has undergone significant restructuring, including selling Formulate for $23 million, shutting down high-overhead operations, and reducing headcount to improve profitability. Despite a challenging market environment, Karkus expressed optimism about raising the stock price above the $1 Nasdaq threshold, leveraging potential liquidity events, and focusing on building revenues and working towards profitability.Prophase Labs Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
ProPhase Labs Appoints Stuart Hollenshead as COO
Positive
Feb 21, 2025
ProPhase Labs appointed Stuart Hollenshead as Chief Operating Officer on February 17, 2025, following Jed Latkin’s departure to pursue other opportunities. Hollenshead, with a history of driving growth in media and consumer platforms, will focus on enhancing the company’s consumer-facing strategy, particularly in direct-to-consumer revenue channels. His appointment aligns with ProPhase’s expansion into science-backed health solutions, including the launch of Legendz and Equivir products. Additionally, the company anticipates significant capital inflow from enhanced accounts receivable initiatives and plans to explore strategic alternatives for Nebula Genomics and DNA Complete. This strategic move is intended to position ProPhase as a leader in the health and wellness industry.
Executive/Board ChangesM&A Transactions
ProPhase Labs Appoints New Chief Operating Officer
Neutral
Feb 13, 2025
ProPhase Labs is negotiating the appointment of Stuart Hollenshead as its new Chief Operating Officer, bringing his extensive marketing experience from 10PM Curfew and Barstool Sports to the company. Following the sale of Pharmaloz Manufacturing, Inc., current COO Jed Latkin announced his departure effective February 14, 2025, to pursue other opportunities, though he will remain as a consultant, and will receive a performance-based bonus for his work in Q1 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.